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Abstract
The relationships between mitochondrial derangements and cell necrosis are exemplified by the changes in the function and
metabolism of mitochondria that occur in the ischemic heart. From a mitochondrial point of view, the evolution of ischemic
damage can be divided into three phases. The first is associated with the onset of ischemia, and changes mitochondria from
ATP producers into powerful ATP utilizers. During this phase, the inverse operation of F0F1 ATPase maintains the
mitochondrial membrane potential by using the ATP made available by glycolysis. The second phase can be identified from
the functional and structural alterations of mitochondria caused by prolongation of ischemia, such as decreased utilization of
NAD-linked substrates, release of cytochrome c and involvement of mitochondrial channels. These events indicate that the
relationship between ischemic damage and mitochondria is not limited to the failure in ATP production. Finally, the third
phase links mitochondria to the destiny of the myocytes upon post-ischemic reperfusion. Indeed, depending on the duration
and the severity of ischemia, not only is mitochondrial function necessary for cell recovery, but it can also exacerbate cell
injury. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
At ¢rst glance, a discussion about the participation
of mitochondria in cell death might seem obvious.
Indeed, the loss of mitochondrial function inevitably
leads to cell necrosis, whereas an optimal energy me-
tabolism is required to preserve cell viability. How-
ever, temporal, qualitative and quantitative aspects
of the multi-faceted relationship between mitochon-
drial function and cell life have still to be elucidated.
For instance, is mitochondrial failure an early step in
the cascade of events leading to cell death? Is the
alteration or the loss of a speci¢c mitochondrial
function necessary to commit cells to death? How
much inhibition of mitochondrial function is re-
quired to jeopardize cell survival?
These and similar questions are the subjects of
other papers in the present thematic issue of Biochi-
mica et Biophysica Acta. Here we summarize the
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changes in the function and metabolism of mitochon-
dria in the ischemic heart to exemplify the complex
relationships between mitochondrial derangements
and cell necrosis. Apoptosis will not be considered
thoroughly, since no information is available on the
possible role of myocardial mitochondria in this type
of cell death. On the other hand, the link between
mitochondria and other myocardial pathologies is
reviewed by Di Mauro in this same issue.
2. Functional and metabolic consequences of ischemia
In the heart, oxygen supply is generally reduced by
coronary obstruction resulting in a critical reduction
of £ow (ischemia). In the a¡ected region deprived of
oxygen, drastic changes of metabolism and lack of
adequate washout determine an abnormal accumula-
tion of ions and metabolites.
2.1. Ischemia and energy metabolism
At a cellular level, the onset of ischemia is deter-
mined by an insu⁄cient availability of oxygen for
mitochondrial oxidations. As a consequence of the
reduced or absent oxidative phosphorylation, intra-
cellular creatine phosphate is rapidly depleted with a
concomitant rise in Pi, both factors stimulating gly-
colysis and lactate production [1]. The accumulation
of lactate and the hydrolysis of ATP decrease intra-
cellular pH. During the early phase of ischemia, the
failure of contraction and the rigor contracture,
which are the most relevant changes in myocardial
function, are caused by intracellular acidosis and se-
vere reduction in ATP content, respectively [1^5].
Besides these relevant functional changes, several cel-
lular activities are modi¢ed by the fall in pH and
ATP content, including the inhibition of glycolysis
which is observed under conditions of severe ische-
mia [6]. A low pH and the accumulation of lactate
decrease the activity of both phosphofructokinase
(PFK) and glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) [6]. It is also likely that PFK activity
becomes depressed owing to the gradual lack of
ATP, although hexokinase, inhibited in deenergized
synaptosomes [7], is active in the ischemic myocardi-
um as shown by the accumulation of glucose-6-phos-
phate [6]. In addition, we have recently shown that
cytosolic proteins bind to myo¢brillar proteins dur-
ing the initial period of ischemia [8]. ATP depletion
appears to be involved in the binding of GAPDH to
myo¢brils, which is associated with the loss of enzy-
matic activity. Similarly, the fall in ATP is associated
with the binding to membranes and inactivation of
PFK [9]. Thus, the failure in mitochondrial ATP
production, which initially stimulates glycogen
breakdown and glycolysis, is followed by the inhib-
ition of the only alternative pathway for energy pro-
duction in the cell.
Mitochondria not only cease to be the major ATP
producers of the cell, but they can also become its
major consumers owing to the hydrolytic activity of
the F0F1 ATPase [10^12]. The inverse operation of
F0F1 ATPase has also been recognized as a promi-
nent pathway for ATP consumption in other cell
types [13,14].
2.2. Mitochondrial information from intact
cardiomyocytes
The temporal relationship between mitochondrial
alterations and the evolution of ischemic damage
cannot be elucidated entirely in the intact organ. In-
deed, the function of mitochondria extracted from a
damaged tissue and assayed in vitro does not allow a
straight appraisal of the behavior of those same mi-
tochondria in situ. The availability of both isolated
cardiomyocytes and a variety of optical probes per-
mitted the study of anoxia at the single cell level.
Isolated cardiomyocytes show a rod shaped mor-
phology and do not display spontaneous contrac-
tions. Rhythmic contractions can be evoked by elec-
trical stimulation. Under deenergizing conditions,
rod shaped myocytes can either change into square
forms (rigor state or contracture) or hypercontract
into rounded dysfunctional forms in which the typi-
cal sarcomeric striature is no longer distinguishable
(hypercontracture) ([15,16], reviewed in [17]).
At the single cell level, hypercontracture is the
paradigm of irreversible damage and is considered
equivalent to the abrupt rise in diastolic pressure in
the absence of contractile activity which is observed
in the intact heart when reperfusion takes place after
prolonged ischemia. However, in the intact heart ir-
reversible damage is characterized by the loss of cell
membrane integrity, easily demonstrated by the re-
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lease of intracellular proteins in the coronary e¥u-
ent. Conversely, hypercontracted myocytes often re-
tain the integrity of sarcolemma, as demonstrated by
the retention of small molecules such as intracellu-
larly trapped £uorescent probes. The di¡erence be-
tween single cells and intact hearts is likely explained
by the lack of cell attachments. The same morpho-
logical distortion which determines the hypercontrac-
ture in isolated myocytes could probably cause the
rupture of the sarcolemma in the intact heart by tear-
ing o¡ adjacent myocytes [18].
In single adult cardiomyocytes the relationship be-
tween cell function and mitochondrial membrane po-
tential (vim) was investigated by using JC-1, a car-
bocyanine derivative [12]. In addition, vim
measurements were compared with the changes in
the intracellular concentration of Mg2 ([Mg2]i)
[12,19]. Since inside the cell most Mg2 is bound to
ATP, [Mg2]i increases mostly as a consequence of a
fall in ATP content [19].
Anoxia does not induce an immediate drop in
vim. If glucose is not removed from the superfusing
bu¡er, myocytes are not a¡ected by a lack of oxygen.
Their ability to twitch is maintained along with no
changes in vim and [Mg2]i. Anoxic changes can be
observed by superfusing or incubating anoxic myo-
cytes in glucose-free media. Under these conditions,
the electrically-stimulated contraction is not modi¢ed
during the initial anoxic phase. After a variable peri-
od of time (15^25 min), contraction fails before rigor
contracture ensues. Only a limited reduction of vim
occurs before asystole. Then, after the failure of con-
traction, ATP content falls, as shown by a gradual
increase in [Mg2]i, which reaches a plateau at the
onset of rigor [19] when vim rapidly collapses [12].
Thus, the onset of rigor is concomitant with ATP
depletion, as it was ¢rst suggested on the basis of
results obtained in myocyte suspensions [21] and
then directly con¢rmed in single myocytes injected
with luciferase [21,22]. Both the contracture and the
fall in vim occur in the absence of major changes in
cytosolic and mitochondrial [Ca2] ([Ca2]c and
[Ca2]m) which rise progressively only after the onset
of ATP-depletion contracture [23]. This sequence of
events has also been reported in myocytes treated
with cyanide and deoxyglucose [24].
These results support the concept that mitochon-
dria maintain their vim by using glycolytically pro-
duced ATP. The fact that an active mitochondrial
ATPase is necessary for the maintenance of vim is
demonstrated by the rapid and complete collapse of
vim occurring in oligomycin-pretreated myocytes
[12,24]. This mechanism does not seem to pertain
exclusively to cardiac myocytes. The acceleration of
anoxia-induced mitochondrial depolarization after
oligomycin administration has also been shown in
carotid body type I cells [25].
2.3. F0F1 ATPase and ANT
Several factors are likely to limit the extent of ATP
hydrolysis by mitochondria in situ. As it has recently
been pointed out by Rouslin, in intact hearts, even in
the presence of uncouplers, the rates of ATP deple-
tion are far lower than those measurable in sonicated
heart mitochondria [26]. ATPase activity is probably
reduced as a consequence of intracellular acidosis. A
pH decrease from 8.0 to 6.0 causes a two-fold reduc-
tion in ATPase activity [26]. In large mammals with
slow heart rates a major role has been attributed to
the ATPase inhibitor protein (IF1) [27], which has
been shown to reduce ATPase activity by 80% or
more [29,30]. This possibility for ATP salvage is
probably limited in small mammals by the scarce
content of IF1 [26,29].
The contribution of adenine nucleotide translocase
(ANT) to ischemic damage is controversial. Under
physiological conditions, the electrogenic exchange
of ADP taken up by mitochondria with ATP re-
leased into the cytosol is driven by vim. The inverse
operation, which is necessary to move the glycolyti-
cally produced ATP into the matrix, could be re-
duced depending on the values of vim which result
from the reverse proton pumping activity of F0F1
ATPase. Thus the build up of vim by means of
ATP hydrolysis would serve as a brake to the further
utilization of cytosolic ATP. However, the fact that
ATP depletion induced by ischemia is slowed by oli-
gomycin [11,30] rules out a primary role for ANT.
On the other hand the inhibition of ANT in the
ischemic heart has been suggested by several reports
[30^32]. One major factor responsible for such inhib-
ition should be the accumulation of long chain acyl-
CoA (LCACoA) which occurs in ischemic hearts as a
consequence of the inhibition of fatty acid oxidation
[30,33,34]. The addition of these CoA esters to iso-
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lated mitochondria inhibits ANT [35] in a process
which is exacerbated by Ca2 [36] and blunted by
several cations such as Mg2 and polyamines
[37,38]. The abundance of these cations in the matrix
could explain the lack of ANT inhibition, when
LCACoA concentration is increased on the matrix
side [39]. In addition, the mitochondrial content of
total CoA (free+esteri¢ed) [33] is below the Ki of
LCACoA for ANT [39] and the concentration of
‘free’ LCACoA is probably reduced in situ by the
binding with various proteins [40], although it is pos-
sible that these esters do not accumulate homogene-
ously, reaching very high local concentrations within
the hydrophobic core of the membranes.
2.4. Structural and functional alterations of
mitochondria in the ischemic heart
The relationship between ischemic damage and mi-
tochondria is not limited to the failure in ATP pro-
duction. Indeed, if the oxygen restriction is main-
tained, mitochondria themselves become targets for
ischemic damage, decreasing the chances of recovery
for both metabolism and function. Mitochondria iso-
lated from ischemic hearts show a pronounced de-
crease in respiration rates in spite of a normal or
slightly reduced capacity for ATP production
[41,42]. An increase in proton leak has been sug-
gested to contribute to such alterations [41].
It has been known for more than 40 years that the
structure of mitochondria is altered by a prolonged
period (i.e., more than 30 min) of ischemia [43,44].
The morphologic changes include swelling, loss of
matrical density and accumulation of dense granules.
In a series of seminal studies Jennings ¢rst linked
these morphological changes to the transition from
reversible to irreversible injury [45] and then demon-
strated that mitochondrial function is also compro-
mised. In particular, mitochondria from ischemic tis-
sues were unable to utilize pyruvate and K-
ketoglutarate, whereas succinate oxidation was al-
most una¡ected [46].
Supporting this initial observation, Complex I ap-
pears to be especially sensitive to ischemic injury [47^
49]. In addition, we found that vim and oxidative
phosphorylation are depressed even with succinate as
the respiratory substrate when mitochondria from
ischemic hearts are exposed in vitro to high Ca2
[50]. The causes for impairment of the respiratory
chain complexes are not known yet. One possible
mechanism could be the generation of oxyradicals
(ROS) which increases in mitochondria harvested
from ischemic hearts [51]. Since ROS are able to
elicit speci¢c damage at the level of respiratory chain
components [52], a vicious cycle of increasing dam-
age could be generated. For instance, the oxidation
of sulfhydryl groups consequent to ROS production
is likely involved in the inhibition of other mitochon-
drial proteins, such as carnitine translocase [53].
Oxygen consumption could be reduced also by the
loss of cytochrome c, which is released in the coro-
nary e¥uent during anoxia in perfused guinea pig
hearts [54]. Since in several cell types a relevant
step of the apoptotic pathway appears to be the ac-
tivation of caspase(s) by cytochrome c upon its re-
lease from mitochondria (see D. Jones’ review in this
same issue), it is tempting to speculate that cyto-
chrome c might also trigger apoptosis in the heart.
This is consistent with the notion that apoptosis oc-
curs together with necrosis in post-ischemic reperfu-
sion [55,56]. Preliminary results suggest that apopto-
sis in human failing hearts is associated with both a
prevalent localization of cytochrome c around myo-
¢brils and caspase activation [57].
Despite the alterations induced by ischemia in the
respiratory chain, upon reperfusion oxidative phos-
phorylation is still active [58] and oxygen consump-
tion is disproportionately high relative to the reduced
contractility [59,60]. Indeed, as mentioned above, mi-
tochondrial function is required both for myocardial
recovery after a short period of ischemia as well as
for its irreparable damage after a prolonged oxygen
deprivation.
2.5. Metabolic derangements
2.5.1. CoA and carnitine
In addition to the above mentioned e¡ects of
LCACoA on ANT, these esters have been recently
shown to inhibit the mitochondrial KATP channel by
interacting with its cytosolic side [61]. This inhibition
could be relevant in the evolution of the ischemic
damage. In fact, agents which inhibit KATP channels
abolish the protective e¡ects exerted by KATP open-
ers against the ischemic damage [62,63]. This bene¢-
cial e¡ect was originally attributed to the opening of
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similar channels located in the plasma membrane
which should produce a cardioplegic e¡ect resulting
from the shortening of the action potential duration
(APD) and the consequent reduction of Ca2 entry.
However, a cardioprotective e¡ect by KATP openers
was demonstrated in the absence of both APD
changes and cardiodepression, ruling out the involve-
ment of the sarcolemma KATP channel [64,65]. On
the other hand, the mitochondrial KATP channel is
likely responsible for the cardioprotection since the
ischemic damage is also reduced by a selective mito-
chondrial KATP opener, diazoxide [66].
It has been suggested that KATP channels are also
involved in preconditioning [67] which is the ability
of a short period of ischemia to protect the heart
from a further prolonged ischemic episode [68].
This phenomenon, which resembles the protection
a¡orded by an initial exposure to sublethal concen-
trations of toxic agents in other cell types [69], im-
plies that the physiological or pharmacological open-
ing of the mitochondrial KATP channel is an early
step in a self-defense mechanism. The maintenance
of ATP contents in ischemic hearts treated with
KATP openers [70] suggests that a reduced rate of
ATP hydrolysis might underlie the cardioprotection.
However, in the absence of an obvious link between
opening of mitochondrial KATP channels and ATP
salvage pathways, the protective mechanism is still
far from being elucidated.
In isolated mitochondria as well as in the intact
heart, LCACoA toxicity could be ascribed in part to
a decreased CoASH availability. The role of CoASH/
esteri¢ed-CoA and carnitine/esteri¢ed carnitine ratios
in the evolution of ischemic damage has been inves-
tigated in isolated rat hearts perfused with glucose-
containing bu¡er both in the presence and absence of
propionate [50]. The ischemic damage was exacer-
bated by propionate owing to the reduction in both
CoASH and carnitine contents. Indeed, the damag-
ing e¡ect of propionate was prevented by carnitine
which restored the ratios between the free and esteri-
¢ed forms of CoA and carnitine.
The relevance of CoASH and carnitine availability
for proper myocardial function is also supported by
other reports. When the energy demand is increased,
i.e., in the working heart perfusion system, propio-
nate a¡ects cardiac performance even under aerobic
conditions and in the presence of glucose [71]. In
addition, in working hearts perfused with acetoace-
tate, a fall in TCA cycle intermediates induced by
inhibition of K-ketoglutarate dehydrogenase was as-
sociated with contractile failure [72,73].
Anoxia or ischemia also result in an increase of the
esteri¢ed/free carnitine ratio [74]. This metabolic
shift, which reproduces the analogous modi¢cation
of CoA status, is caused by the inhibition of mito-
chondrial dehydrogenases consequent to the excess
of reduced £avin and pyridine coenzymes. The re-
duced rates of both L-oxidation and the TCA cycle
freeze CoA in the form of LCACoA or SCACoA,
while available carnitine acts as a scavenger of acyl
moieties to liberate CoA. This action of carnitine
appears to be pertinent to pyruvate utilization. In
fact, in hypoxic tissues pyruvate is mostly converted
to lactate due to PDH inhibition. By decreasing the
acetyl-CoA/CoA ratio, carnitine might stimulate
PDH, thus diverting pyruvate from reduction to lac-
tate and causing its oxidation to acetyl-CoA and
then acetylcarnitine. Experimental and clinical evi-
dence supports these concepts. Glucose oxidation is
stimulated by carnitine in isolated hearts perfused
under both normoxic and ischemic conditions
[75,76]. In addition, carnitine administration was
shown to reduce lactate formation in subjects su¡er-
ing from coronary artery disease [77]. Similar results
were also obtained in patients su¡ering from inter-
mittent claudication [78].
2.5.2. Pyridine nucleotides
While several studies documented the expected in-
crease in NADH(H)/NAD ratio following a crit-
ical reduction in tissue oxygenation [79,80], the
changes in the total content of pyridine nucleotides
(PN) have been overlooked. Since the majority of PN
is located within the mitochondrial matrix, it would
be important to determine if the decrease in PN con-
tent induced by ischemia [81,82] occurs to the same
extent in every cell compartment. In any case, a se-
vere reduction in PN content implies that the mito-
chondrial pool is also a¡ected. This appears to be the
case upon post-ischemic reperfusion when tissue PN
content is reduced to less than 30% of that measur-
able in normoxic controls (F. Di Lisa et al., unpub-
lished data). Then the problem becomes that of the
possible mechanisms causing the disappearance of
mitochondrial PN. In isolated mitochondria a rapid
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PN depletion is obtained upon incubation in the
presence of high [Ca2] [83,84]. It has been proposed
that NAD is hydrolyzed by a Ca2-stimulated gly-
cohydrolase located in the matrix [85]. Subsequently,
ADP ribose formed by this hydrolysis would stimu-
late, by means of covalent modi¢cation, an intrinsic
protein of the inner mitochondrial membrane which
was suggested to be part of a speci¢c pathway for
mitochondrial Ca2 e¥ux [86]. Such a mechanism
was not supported by a careful investigation of the
location of NAD glycohydrolase, which rather
ruled out its presence within the matrix space [87].
Accordingly, the PN pool of mitochondria can be
hydrolyzed only upon its release into the intermem-
brane space. It is tempting to speculate that such an
e¥ux might occur by means of MTP opening. This
hypothesis is supported by the inhibition of mito-
chondrial PN degradation by CsA [88] which lacks
any e¡ect on NAD glycohydrolase (F. Di Lisa et
al., unpublished data). Thus, the measurement of
mitochondrial PN content could represent a valuable
tool for investigating MTP opening in intact cells or
tissues.
3. Mitochondria in the transition from reversible to
irreversible injury
Prolongation of ischemia (i.e., more than 20 min
of no £ow ischemia in perfused hearts) leads myo-
cytes to a point of no return beyond which even
readmission of oxygen fails to rescue cell viability.
The concept of irreversible damage was originally
de¢ned by Jennings in 1957 as ‘‘injury of su⁄cient
severity and duration that the involved cells will con-
tinue to degenerate and become necrotic despite re-
oxygenation by reperfusion of arterial blood’’ [44]
(for a review of these early observations see [89]).
Myocardial tissue exhibits a peculiar transition
from reversible to irreversible damage. In every cell
type the lack of ATP production and a severe de-
crease of its content result in a slow degenerative
process which eventuates in the loss of plasma mem-
brane integrity with release of intracellular compo-
nents. Thus, if the initial pathological stimulus (i.e.,
lack of oxygen) is not removed, the inhibition or the
alteration of mitochondrial function result in cell
death. In addition to this common mode of cell
death, which occurs gradually, the myocardium ex-
hibits a peculiar transition to irreversible injury,
which occurs suddenly when oxygen supply is rees-
tablished after a prolonged period of ischemia [89].
In this case the uncontrolled hypercontracture of my-
o¢laments is associated with a rapid increase of cell
membrane permeability followed by the release of
intracellular constituents, such as enzymes [18,89].
The sudden changes produced by reperfusion on my-
ocardial viability were concomitant with massive ac-
cumulation of calcium within the mitochondrial ma-
trix [90,91].
This seminal ¢nding highlighted the role of intra-
cellular Ca2 overload in myocardial pathology.
However, the cautious comment of Jennings
(‘‘whether the calcium uptake is causally related to
the development of irreversibility remains to be in-
vestigated’’ [90,91]), was later overlooked by many
investigators. In addition, the ¢nding of mitochon-
drial calcium precipitates in situ as well as in isolated
mitochondria [92] prompted a widespread interpreta-
tion of mitochondrial Ca2 uptake as a pathological
process. Only during the 1980’s and early 1990’s did
mitochondrial Ca2 homeostasis gain back its rele-
vance in cell physiology owing to the recognition of
the Ca2 requirement for the activity of several de-
hydrogenases (reviewed in [93,94]), as shown for the
¢rst time with K-glycerophosphate dehydrogenase
[95].
The mechanisms underlying the onset of irreversi-
ble damage are still a matter of debate and a detailed
discussion about the various hypotheses is outside
the scope of the present paper [96^99]. What is rele-
vant for this review is that the rapid transition to-
wards cell death requires a coupled mitochondrial
respiration. This apparent paradox was ¢rst reported
by Ganote, who demonstrated that cyanide blunted
the enzyme release which occurs upon post-ischemic
reperfusion in rat hearts [100]. Subsequently, the in-
hibition of the respiratory chain or the addition of
uncouplers of oxidative phosphorylation were shown
to limit the extent of enzyme release in di¡erent mod-
els of myocardial damage such as post-ischemic re-
perfusion [101], calcium paradox (reintroduction of
Ca2 after Ca2-free perfusion) and oxygen-paradox
(readmission of oxygen after anoxia) [102,103]. These
¢ndings, obtained on perfused hearts and isolated
myocytes, suggest that restoration of ATP produc-
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tion by mitochondrial oxidative phosphorylation is
essential for cell recovery, but can also contribute
to the processes causing cell necrosis.
It could be hypothesized that upon reoxygenation
mitochondria accumulate Ca2 rather than produc-
ing ATP. The consequent failure of the mechanisms
which extrude Ca2 out of the sarcoplasm would
result in a vicious cycle of a massive intracellular
Ca2 rise and mitochondrial derangement. In addi-
tion, the rise in [Ca2]i could promote opening of the
cyclosporin-sensitive mitochondrial permeability
transition pore, leading to a sudden vim dissipation
(as reviewed in [104] and in this same issue by A.
Halestrap). In general, any conditions associated
with intracellular Ca2 overload eventually result in
hypercontracture. Under these circumstances, the in-
crease in [Ca2]i precedes vim collapse [105]. For
instance, in isolated cardiomyocytes exposed to con-
ditions which determine Ca2 overload, such as Ca2
paradox (i.e., Ca2 readmission to myocytes previ-
ously bathed in the absence of Ca2), a transient
increase in vim is followed by its rapid and persis-
tent collapse [105]. However, studies on isolated my-
ocytes provide clear evidence that the transition to-
wards the point of no return does not require Ca2
overload and mitochondrial failure. In fact, upon
reoxygenation, vim is partially restored independent
of recovery of mechanical function, as demonstrated
by the fact that FCCP addition is able to induce a
further fall of vim in hypercontracted myocytes [12].
vim is likely utilized to produce ATP since, irrespec-
tive of the functional outcome, [Mg2]i decreases
gradually to control levels [12,19]. Similarly, the re-
moval of metabolic inhibition (cyanide plus deoxy-
glucose) was shown to induce hypercontracture
along with a sudden recovery of ATP contents in
cardiomyocytes microinjected with luciferase [22].
As far as Ca2 homeostasis is concerned, reoxygen-
ation is followed by a rapid fall of [Ca2]c towards
preanoxic levels [23,106], whereas [Ca2]m shows a
modest and transient decrease which is followed by
a secondary rise. Interestingly, it appears that anoxic
levels of [Ca2]m are inversely related to the proba-
bility of cell recovery upon reoxygenation, suggesting
that even a slight increase in intramitochondrial Ca2
levels could a¡ect the anoxic damage [23].
Di¡erent e¡ects of reoxygenation on intracellular
[Ca2] have been reported in cardiomyocytes from
other animal species. For instance, in guinea pig car-
diomyocytes a transient [Ca2]c rise [107,108] was
related to the abundance of the sarcolemmal Na/
Ca2 exchanger in this species [109]. Nevertheless,
since in isolated myocytes the irreversible damage
occurs in the absence of large changes in intracellular
Ca2, the large increase in tissue calcium which is
observed in the intact heart upon reperfusion is
probably the consequence rather than the cause of
sarcolemma rupture. In addition, the recovered vim
is utilized mostly to increase the cellular ATP content
rather than to ¢ll mitochondria with Ca2.
If vim is restored, ATP content increases and in-
tracellular Ca2 is not increased. Why, then, is mito-
chondrial function required to cause hypercontrac-
ture or tissue injury upon reoxygenation? This
apparent paradox is probably related to the di¡erent
ATP requirements of contraction and relaxation at
the myo¢lament level, as shown by the elegant study
of Altschuld et al. on permeabilized myocytes [110].
In this model, the absence of ATP produced contrac-
ture, whereas hypercontrature was obtained in the
presence of submillimolar concentrations of ATP.
Although these changes could be produced in the
presence of EGTA, Ca2 increased the ATP require-
ments for the maintenance or the recovery of the
elongated morphology. Accordingly, a suboptimal
mitochondrial function could produce low levels of
ATP which, in the presence of even a modest rise in
[Ca2]i, might be su⁄cient for the formation of rigor
bonds but not for the relaxation process, resulting in
the hypercontracture. These concepts were validated
by using 2,3-butanedione monoxime (BDM) which
inhibits contraction by both interacting with myosin
and reducing the sensitivity of myo¢brils to Ca2.
Indeed, when anoxic cardiomyocytes were supple-
mented with BDM just prior to reoxygenation, hy-
percontracture was prevented and the cells recovered
their elongated morphology upon BDM withdrawal
[111]. Since enzyme release from the reperfused heart
is reduced by BDM as well [112], the hypercontrac-
ture appears to be a primary event in the generation
of the irreversible damage. Thus, the severe intracel-
lular calcium overload which follows the rupture of
the plasma membrane would be in most cases the
consequence rather than the cause of cell death.
This concept should be taken into account when
Ca2-dependent activities are suggested as causative
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factors in the generation of the irreversible damage.
For instance, based on the available evidence [113]
the cause-e¡ect relationship between MTP opening
and reperfusion requires remains a matter of debate
[104]. In a very fast sequence of events MTP opening
could be the initiator of the process leading to sar-
colemma rupture and enzyme release or it could be
just one of the consequences of the intracellular
£ooding with extracellular Ca2. The powerful coop-
eration between cellular and molecular biology will
undoubtedly help solve this question, and will be
instrumental in clarifying the mechanisms by which
mitochondria rule the complex balance between life
and death.
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